Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation-Reference-Cited by-同舟云学术

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

Published:2014-10-15 Issue:5 Volume:168 Page:663-670
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Straus David J.¹,Hamlin Paul A.¹,Matasar Matthew J.¹,Lia Palomba Maria¹,Drullinsky Pamela R.²,Zelenetz Andrew D.¹,Gerecitano John F.¹,Noy Ariela¹,Hamilton Audrey M.³,Elstrom Rebecca⁴,Wegner Brett¹,Wortman Katy⁵,Cella David⁵

Affiliation:

1. Memorial Sloan-Kettering Cancer Center; Division of Hematologic Oncology; Lymphoma Service; New York NY USA

2. Memorial Sloan-Kettering Rockville Centre; Rockville Centre NY USA

3. Memorial Sloan-Kettering Basking Ridge; Basking Ridge NJ USA

4. Department of Medicine; Weill Cornell Medical College; Chicago IL USA

5. Northwestern University Feinberg School of Medicine; Chicago IL USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13195/fullpdf

Reference34 articles.

1. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria;Aribi;J Cancer Res Ther,2010

2. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G);Brucker;Evaluation and the Health Professions,2005

3. Development of a measure of health-related quality of life fo non-Hodgkin's lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym);Cella;Blood (ASH Annual Meeting Abstracts),2005

4. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma;Chao;Blood,1990

5. Revised response criteria for malignant lymphoma;Cheson;Journal of Clinical Oncology,2007

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma;PharmacoEconomics - Open;2024-01-10

2. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma;Journal of Pharmacology and Experimental Therapeutics;2023-10-24

3. Clinical advances in epigenetic therapies for lymphoma;Clinical Epigenetics;2023-03-04

4. Epigenetic targets in B- and T-cell lymphomas: latest developments;Therapeutic Advances in Hematology;2023-01

5. Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study;Annals of Translational Medicine;2021-12